ReviewFrontiers in endocrinology2026
Peripheral artery disease in diabetes.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral artery disease in diabetes mellitus represents a distinct clinical entity characterized by diffuse distal arterial disease, medial calcification, microvascular dysfunction, neuropathy, and a pro-thromboinflammatory milieu. These features contribute to atypical presentations, diagnostic challenges, accelerated progression, and elevated risks of limb loss and cardiovascular events. Management requires integrated strategies encompassing metabolic optimization, lifestyle modification, pharmacotherapy, antithrombotic therapy, supervised exercise, and timely revascularization. Emerging approaches, including GLP-1 receptor agonists, SGLT2 inhibitors, and regenerative therapies, show promise in improving vascular, functional, and limb outcomes. Advancing outcomes in diabetic peripheral artery disease will depend on mechanism-driven screening, individualized therapies, and novel interventions to prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.